Skip to main content

Table 2 Adverse events observed in patients administered adjuvant chemotherapy with DCS

From: Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer

Toxicity

No. of patients (%)

Grade 3 or higher

All

Hematological toxicity

 Neutropenia

3

(10.0)

14

(46.7)

 Leukopenia

3

(10.0)

12

(40.0)

 Anemia

2

(6.7)

10

(33.3)

 Thrombocytopenia

0

(0.0)

8

(26.7)

 Febrile neutropenia

4

(13.3)

4

(13.3)

Non-hematological toxicity

 Nausea

1

(3.3)

19

(63.3)

 Diarrhea

1

(3.3)

6

(20.0)

 Anorexia

4

(13.3)

22

(73.3)

 Fatigue

3

(10.0)

23

(76.7)

 Stomatitis

0

(0.0)

5

(16.7)

 Abdominal distension

0

(0.0)

2

(6.7)

 Alopecia

0

(0.0)

17

(56.7)

 Dry skin

0

(0.0)

2

(6.7)

 Dysgeusia

0

(0.0)

3

(10.0)

 Skin pigmentation

0

(0.0)

4

(13.3)